Related Experiment Video

Updated: Feb 12, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K

Endovascular Treatment Alone vs. Endovascular Treatment Plus Rheocarna for Patients With Chronic Limb-Threatening

Takahiro Tokuda1, Naoki Yoshioka2, Akiko Tanaka3

  • 1Department of Cardiology, Nagoya Heart Center Nagoya Japan.

Circulation Reports
|February 11, 2026
PubMed

Insights

Rheocarna® significantly improved wound healing in patients with chronic limb-threatening ischemia (CLTI) and small artery disease (SAD2) after endovascular treatment (EVT). This suggests Rheocarna may benefit specific CLTI patients undergoing EVT.

Area of Science:

  • Vascular Surgery
  • Regenerative Medicine
  • Clinical Research

Background:

  • Chronic limb-threatening ischemia (CLTI) poses a significant clinical challenge.
  • Endovascular treatment (EVT) is a common intervention for infrainguinal lesions.
  • Evaluating adjunct therapies to improve outcomes after EVT is crucial.

Purpose of the Study:

  • To assess the impact of Rheocarna® as an adjunct therapy following EVT in CLTI patients.
  • To compare wound healing rates and other clinical outcomes between EVT alone and EVT with Rheocarna®.
  • To identify patient subgroups who may benefit most from Rheocarna®.

Main Methods:

  • Retrospective analysis of 913 CLTI patients undergoing EVT for infrainguinal lesions.
  • Patients grouped into EVT alone or EVT with Rheocarna®.
  • Propensity score matching (PSM) used to control for baseline differences; 88 matched pairs analyzed.
  • Primary outcome: 1-year wound healing rate; secondary outcomes: healing time, amputation, reintervention.

Main Results:

  • In patients with small artery disease (SAD2), the EVT plus Rheocarna® group showed a significantly higher 1-year wound healing rate (66.6%) compared to EVT alone (26.0%; P=0.01).
  • No significant differences were observed between groups for wound healing time, major amputation rate, or reintervention rate at 1 year.
  • PSM successfully balanced baseline characteristics between the 88 matched pairs.

Conclusions:

  • Adjunctive Rheocarna® therapy significantly improved 1-year wound healing rates in CLTI patients with SAD2 undergoing EVT.
  • Rheocarna® did not significantly impact wound healing time, major amputation, or reintervention rates in this cohort.
  • Patients with CLTI and SAD2 may be suitable candidates for Rheocarna® treatment post-EVT.
Abstract

Keywords:
Chronic limb-threatening ischemiaRheocarnaSmall artery disease

More Related Videos

Simulator Training for Endovascular Neurosurgery08:08

Simulator Training for Endovascular Neurosurgery

Published on: May 6, 2020

4.2K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

2.0K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
975
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K